Molecular monitoring of low grade non-hodgkin’s lymphoma by gene amplification
Authors: Hickish, T.F., Purvies, H., Mansi, J., Soukop, M. and Cunningham, D.
Journal: British Journal of Cancer
Volume: 64
Issue: 6
Pages: 1161-1163
eISSN: 1532-1827
ISSN: 0007-0920
DOI: 10.1038/bjc.1991.482
Abstract:Molecular monitoring by the polymerase chain reaction was used to detect and follow minimal disease in working formulation category B and C on non-Hodgkin’s lymphoma. Rearrangement of the bcl-2 gene served as the target for gene amplification. Thirty patients were studied. Bone marrow histology was compared to PCR analysis of bone marrow aspirate and blood. PCR upstaged disease status in approximately 50% of patients. Results are shown from a patient whose disease was followed with PCR during chemotherapy from initial remission to relapse. We conclude that PCR of bone marrow and blood can be used to upstage disease status in low grade lymphoma and PCR of blood may be used to monitor response to treatment with obvious patient benefit. The general approach of molecular monitoring provides a means for appraising therapies in the setting of subclinical disease. © Macmillan Press Ltd., 1991.
Source: Scopus
Preferred by: Tamas Hickish
Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification.
Authors: Hickish, T.F., Purvies, H., Mansi, J., Soukop, M. and Cunningham, D.
Journal: Br J Cancer
Volume: 64
Issue: 6
Pages: 1161-1163
ISSN: 0007-0920
DOI: 10.1038/bjc.1991.482
Abstract:Molecular monitoring by the polymerase chain reaction was used to detect and follow minimal disease in working formulation category B and C on non-Hodgkin's lymphoma. Rearrangement of the bcl-2 gene served as the target for gene amplification. Thirty patients were studied. Bone marrow histology was compared to PCR analysis of bone marrow aspirate and blood. PCR upstaged disease status in approximately 50% of patients. Results are shown from a patient whose disease was followed with PCR during chemotherapy from initial remission to relapse. We conclude that PCR of bone marrow and blood can be used to upstage disease status in low grade lymphoma and PCR of blood may be used to monitor response to treatment with obvious patient benefit. The general approach of molecular monitoring provides a means for appraising therapies in the setting of subclinical disease.
Source: PubMed
MOLECULAR MONITORING OF LOW-GRADE NON-HODGKINS-LYMPHOMA BY GENE AMPLIFICATION
Authors: HICKISH, T.F., PURVIES, H., MANSI, J., SOUKOP, M. and CUNNINGHAM, D.
Journal: BRITISH JOURNAL OF CANCER
Volume: 64
Issue: 6
Pages: 1161-1163
ISSN: 0007-0920
DOI: 10.1038/bjc.1991.482
Source: Web of Science (Lite)
Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification.
Authors: Hickish, T.F., Purvies, H., Mansi, J., Soukop, M. and Cunningham, D.
Journal: British journal of cancer
Volume: 64
Issue: 6
Pages: 1161-1163
eISSN: 1532-1827
ISSN: 0007-0920
DOI: 10.1038/bjc.1991.482
Abstract:Molecular monitoring by the polymerase chain reaction was used to detect and follow minimal disease in working formulation category B and C on non-Hodgkin's lymphoma. Rearrangement of the bcl-2 gene served as the target for gene amplification. Thirty patients were studied. Bone marrow histology was compared to PCR analysis of bone marrow aspirate and blood. PCR upstaged disease status in approximately 50% of patients. Results are shown from a patient whose disease was followed with PCR during chemotherapy from initial remission to relapse. We conclude that PCR of bone marrow and blood can be used to upstage disease status in low grade lymphoma and PCR of blood may be used to monitor response to treatment with obvious patient benefit. The general approach of molecular monitoring provides a means for appraising therapies in the setting of subclinical disease.
Source: Europe PubMed Central